



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 6, 2001

LAW OFFICES OF JONATHAN ALAN QUINE

By Alexandra Allison
Alexandra Allison

Attorney Docket No. 31-001100US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anders Hjelholt Pedersen, et al.

Application No.: 09/782,587

Filed: February 12, 2001

For: FACTOR VII OR VIIA-LIKE
MOLECULES

Examiner: Unassigned

Art Unit: Unassigned

COMUNICATION TO THE EXAMINER
REGARDING SEQUENCE LISTING

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The accompanying sequence listing is be submitted in response to the missing parts dated May 9, 2001. Please amend the specification as follows:

Page 45, lines 7-20:

The identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material. A number of suitable tags are commercially available, e.g., from Unizyme Laboratories, Denmark. For instance, the tag can consist of any of the following sequences: (SEQ ID NOS 12-16, respectively)

His-His-His-His-His

Met-Lys-His-His-His-His-His

Met-Lys-His-His-Ala-His-His-Gln-His-His

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-Gln

or any of the following: (SEQ ID NOS 17-19, respectively)

EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)